Adverse Drug Event Reports
Buy and sell adverse drug event reports data. Side effects, reactions, drug interactions logged in real time — pharmacovigilance AI needs more than FDA reports.
No listings currently in the marketplace for Adverse Drug Event Reports.
Find Me This Data →Overview
What Is Adverse Drug Event Reports Data?
Adverse drug event (ADE) reports capture real-time data on side effects, drug interactions, and unexpected reactions logged by healthcare providers, patients, and manufacturers. Beyond FDA's MedWatch system, this data streams from electronic health records, clinical notes, spontaneous reporting networks, and post-market surveillance—providing pharmaceutical companies and AI systems early warning signals for safety issues that may not emerge until after Phase III trials or market approval. Pharmacovigilance AI platforms depend on high-volume, granular ADE datasets to detect rare events, identify at-risk populations, and predict drug interactions before they cause serious harm or trigger recalls.
Market Data
Increasing reports, especially novel/serious events
Cardiac therapy drug adverse events in China market
Source: BMJ Open
2,545,184 records (2012–2019)
U.S. prescription records analyzed for ADE patterns
Source: Journal of Medical Internet Research
FDA lagged in regulating postmarket surveillance and ADE reports from MedWatch
Critical post-market gap
Source: PubMed Central
Drug interactions and efficacy often discovered after Phase III trials and FDA approval (Phase IV)
Major discovery window
Source: PubMed Central
Who Uses This Data
What AI models do with it.do with it.
Pharmacovigilance AI Systems
Machine learning models extract ADE signals from clinical narratives, electronic health records, and social media to detect rare events and emerging safety patterns faster than traditional reporting.
Pharmaceutical Manufacturers
Post-market surveillance teams monitor Phase IV trials and real-world ADE data to identify new drug restrictions, dosing adjustments, population-specific warnings, or market opportunities.
Insurance Payers & Health Systems
Payers use ADE data to support outcomes-based drug pricing, medication management, and clinical decision support systems that reduce prescription errors and serious adverse events.
Regulatory Agencies
FDA and national regulators track ADE trends to issue safety advisories, recalls, or labeling updates—as seen with Vioxx withdrawal in 2004.
Pricing depends on the proposed terms
We do not have a verified, comparable price for your dataset. Consider the permitted uses, license term, exclusivity, provenance, coverage and quality. A seller asking price is a proposal, not an appraisal or guaranteed sale. Compare prices only when the source, date, currency, unit and license scope are known.
What Buyers Expect
What makes it valuable.valuable.
Temporal Accuracy & Completeness
Events must include onset date, reporting date, and drug exposure timeline. Missing data fields reduce buyer confidence and AI model performance.
De-identification & Privacy Compliance
Patient identifiers must be removed per FDA regulations. Retain sufficient clinical context (age, gender, concomitant drugs, outcomes) for signal detection.
Standardized Coding
Use MedDRA (Medical Dictionary for Regulatory Activities) for adverse event terms and ATC classification for drugs to ensure interoperability with buyer systems.
Outcome & Severity Documentation
Serious adverse events (hospitalization, death, disability) must be clearly flagged. Buyers prioritize high-confidence, well-documented cases for model training.
Medication Error & Drug-Drug Interaction Data
Include concomitant drug lists, dosing errors, and suspected causal associations to maximize value for pharmacovigilance AI.
Potential applications and organizations
Who's buying.buying.
Post-market surveillance, Phase IV trials, outcomes-based drug pricing agreements tied to real-world ADE data.
Value-based drug pricing and clinical decision support tied to ADE reduction; risk mitigation.
Train machine learning models to detect drug safety signals and adverse reactions from EHR text and spontaneous reports.
FAQ
Common questions.questions.
What is the difference between FDA MedWatch data and broader ADE report datasets?
MedWatch is the FDA's official adverse event reporting system, but it suffers from underreporting and regulatory lag. Broader ADE datasets include spontaneous reports from hospitals, EHR systems, social media, and real-world insurance claims—providing richer, real-time signals that AI systems can detect before formal FDA action.
Why is post-market (Phase IV) ADE data valuable if the drug is already approved?
Many serious drug interactions, long-term effects, and safety risks affecting specific populations (pregnant women, children, elderly) emerge only after a drug hits the market and is used in millions of patients. Phase IV data has identified major safety issues leading to recalls, restrictions, and new market opportunities—like Vioxx withdrawal in 2004.
How do insurers and payers use ADE data for drug pricing?
Health insurers increasingly tie drug prices to real-world outcomes and safety performance. Companies like Cigna, Aetna, CVS, and Express Scripts negotiate pay-for-performance deals where drug prices adjust based on actual adverse event rates and treatment efficacy in their patient populations.
What coding standards do buyers require for ADE datasets?
Buyers expect adverse events coded in MedDRA (Medical Dictionary for Regulatory Activities) and drugs classified by ATC (Anatomical Therapeutic Chemical) to ensure compatibility with their pharmacovigilance systems and regulatory submissions. Standardized coding significantly increases data value.
Sell youradverse drug event reportsdata.
Describe your adverse drug event reports and the uses you are authorized to offer. Price, legal suitability, and buyer interest require separate evaluation. No match or sale is guaranteed.
Prepare a Listing